Application of Telemedicine to the Management of Aggressive Lymphomas (AMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03336138
Recruitment Status : Recruiting
First Posted : November 8, 2017
Last Update Posted : November 8, 2017
Information provided by (Responsible Party):
University Hospital, Toulouse

Brief Summary:
The purpose of this study is to evaluate the value of AMA in a comparative multicenter regional study as a reference for aggressive lymphoma. The primary endpoint will be RDI. This study consider that the AMA support should allow a significant improvement of the RDI compared to the control group and thus impact the duration without progression. The study covers 350 patients recruited from 10 regional centers.

Condition or disease Intervention/treatment Phase
Lymphoma Other: AMA (Assistance for ambulatory patients) Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 350 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Application of Telemedicine to the Management of Aggressive Lymphomas: a Regional Comparative Study
Actual Study Start Date : January 2012
Estimated Primary Completion Date : January 2018
Estimated Study Completion Date : January 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Active Comparator: AMA group
Patient with telephone follow-up modality called AMA (Assistance for ambulatory patients)
Other: AMA (Assistance for ambulatory patients)
telephone follow-up modality

No Intervention: Control group
Patient with standard follow-up with no specific assistance for ambulatory patients

Primary Outcome Measures :
  1. dose-relative intensity (RDI) [ Time Frame: through study completion, an average of 2 years ]
    reduction of RDI

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient with a recent diffuse large B cell lymphoma (LBDGC), histologically proven, with treatment not started
  • a priori likely to be treated by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP21) for 8 cycles or rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP).
  • Index international prognosis (IPI) measurable (IPI-aa), adjusted for age. Any IPI-aa is eligible.
  • accepting the study

Exclusion Criteria:

  • Patient with another type of lymphoma (including transformed follicular forms)
  • Patient having already started his treatment.
  • Life expectancy <3 months.
  • Carcinologic history
  • Serum positive for HIV or hepatitis B virus (HBV).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03336138

Contact: LAURENT Guy, MD
Contact: COMPACI Gisèle, Nurse

Clinique Claude Bernard Recruiting
Albi, France, 81000
Contact: Houyau Philippe, MD         
Hospital Recruiting
Auch, France, 32000
Contact: Vaillant Willy, MD         
Bayonne Hospital Recruiting
Bayonne, France, 64000
Contact: Banos Anne, MD         
University Hospital Bordeaux Recruiting
Bordeaux, France, 33000
Contact: Fitoussi Olivier, MD         
Hospital Recruiting
Montauban, France, 82000
Contact: Carrero Miguel, MD         
Clinique Marzet Recruiting
Pau, France, 64000
Contact: Schlaifer Daniel, MD         
Rodez Hospital Recruiting
Rodez, France, 12000
Contact: Mosser Laurent, MD         
Tarbes Hospital Recruiting
Tarbes, France, 65000
Contact: Dingremont Claire, MD         
Clinique Saint Jean Recruiting
Toulouse, France, 31000
Contact: Suc Etienne, MD         
University Hospital of Toulouse Recruiting
Toulouse, France
Contact: LAURENT Guy, MD         
Sponsors and Collaborators
University Hospital, Toulouse
Principal Investigator: LAURENT Guy, MD University Hospital, Toulouse

Responsible Party: University Hospital, Toulouse Identifier: NCT03336138     History of Changes
Other Study ID Numbers: RC31/12/0072
First Posted: November 8, 2017    Key Record Dates
Last Update Posted: November 8, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases